Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose among the key challenges ...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

NEWARK, Del, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The Narcolepsy Treatment Market 2024 to 2034 is expected to experience substantial growth, with the market size projected to expand from USD 5,301.6 ...

AXS-12 is an investigational highly selective potent norepinephrine reuptake inhibitor and cortical dopamine modulator.

NEWARK, Del, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The Narcolepsy Treatment Market 2024 to 2034 is expected to experience substantial growth, with the market size projected to expand from USD 5,301.6 ...

(MENAFN- GlobeNewsWire - Nasdaq) Narcolepsy treatment market by Product (Narcolepsy Treatment Drugs and Devices), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, e-commerce ...

Research and development activities, coupled with a rising demand for effective narcolepsy treatments, are additional factors fueling market expansion. However, challenges such as low per capita ...

Axsome's AXS-12 reduces narcolepsy symptoms, positioning the company for success. Find out why AXSM stock is a buy with ...

NLS Pharmaceutics (NLSP) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now ...

AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) ...

Centessa's pipeline is anchored by two main drug candidates: ORX750 for narcolepsy and SerpinPC for hemophilia B. These innovative treatments are positioned to potentially disrupt their respective ...